以色列梯瓦制药工业集团近日以74亿美元现金加股票方式收购美国的Ivax,从而重新夺回了全球最大仿制药生产商头衔。业界认为此举意味着双方已默认仿制药行业竞争日趋激烈的局面不会迅速得到改变。梯瓦做大,为避竞争?不少原研药的专利保护将在2006年至2007年间到期,许多仿制药公 Israel’s Teva pharmaceutical industry group recently to the US $ 7.4 billion cash and stock acquisition of the United States Ivax, thereby regaining the title of the world’s largest generic drug manufacturer. The industry believes that this means that the two sides have acquiesced in the increasingly competitive generic industry will not be rapidly changing situation. Ladder tile bigger, to avoid competition? A lot of patent protection of the original research will expire between 2006 and 2007, many generic drugs